Toshiba America Medical Solutions has received U.S. Food and Drug Administration (FDA) clearance for its new Aplio i900 cardiovascular ultrasound scanner.
The company is showcasing the new scanner and other cardiovascular care products at this week's American College of Cardiology (ACC) meeting in Washington, DC.
The latest addition to the Aplio i-series platform, Aplio i900 brings premium cardiac imaging to the daily clinical routine, helping healthcare facilities provide more cost-effective, less invasive, and safer cardiovascular care, Toshiba said.
The system offers new features that allow clinicians to easily assess myocardial function or quantify complex valvular lesions with improved image detail, the company said. Designed for optimal fetal, pediatric, stress echo, and transesophageal echocardiography imaging, the i900 provides ultrafast processing power that helps providers see more in their ultrasound exams thanks to thinner beam slices and more return information in each image.
Toshiba's new iBeam beamforming technology optimizes the efficiency of the beam, increasing penetration, spatial resolution, and contrast resolution, Toshiba said. With new ergonomic features, Aplio i900 also offers improved productivity during exams with iSense, touch control screens, and a real-time quick scan option.
In other cardiac offerings at ACC 2017, Toshiba will demonstrate its forward projected model-based iterative reconstruction solution (FIRST) for cardiac exams. Available on Toshiba's Aquilion One Genesis and Aquilion One Vision CT systems, FIRST boosts the safety of CT exams while reducing noise.
